Current Edition:

Table of Contents

Editor's Note Neil Love, MD

Michael Baum, ChM, FRCS

Summary and implications of ATAC trial results   Reduction in contralateral breast cancers   Safety profile of anastrozole   Bisphosphonates combined with anastrozole   Neoadjuvant use of aromatase inhibitors   The value of screening mammography References on aromatase inhibitors in breast cancer management and the value of screening mammography

Mark Pegram, MD

Overview of HER2 biology and evaluation of HER2 assays   Mechanism of antitumor action of trastuzumab   Management of HER2-positive patients   Duration and scheduling of trastuzumab treatment   Hormonal therapy in combination with trastuzumab   Trastuzumab in the adjuvant setting References on the assessment of HER2 and the role of trastuzumab in the adjuvant and metastatic setting

Robert Livingston, MD

Proposed Intergroup adjuvant study of AC followed by docetaxel +/- capecitabine   Capecitabine/docetaxel (XT) combination in clinical practice   Clinical trials of antitubulin combinations   Treatment algorithm for HER2-positive/negative metastatic breast cancer   Combination versus single agent chemotherpy for advanced disease   Duration of trastuzumab therapy   PET scanning with labeled estrogens References on metronomic dosing of chemotherapy; capecitabine and docetaxel alone or in combination for metastatic breast cancer; PET imaging of estrogen receptors